StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
10
Publishing Date
2023 - 12 - 18
10
2023 - 12 - 13
8
2023 - 12 - 12
11
2023 - 12 - 11
13
2023 - 11 - 03
10
2023 - 11 - 02
8
2023 - 10 - 30
8
2023 - 10 - 16
10
2023 - 09 - 26
10
2023 - 09 - 07
8
2023 - 07 - 17
12
2023 - 06 - 05
13
2023 - 05 - 25
10
2023 - 05 - 16
11
2023 - 05 - 09
8
2023 - 04 - 26
10
2023 - 04 - 17
8
2023 - 03 - 28
8
2023 - 02 - 16
8
2022 - 11 - 03
9
2022 - 09 - 16
9
2022 - 07 - 28
8
2022 - 06 - 22
9
2022 - 06 - 10
9
2022 - 05 - 23
8
2022 - 02 - 25
9
2022 - 02 - 14
9
2021 - 12 - 13
19
2021 - 12 - 09
16
2021 - 12 - 06
8
2021 - 11 - 30
8
2021 - 11 - 29
12
2021 - 11 - 15
9
2021 - 11 - 12
12
2021 - 11 - 09
7
2021 - 11 - 08
8
2021 - 10 - 25
8
2021 - 10 - 15
9
2021 - 10 - 07
7
2021 - 10 - 04
8
2021 - 09 - 29
7
2021 - 09 - 28
7
2021 - 09 - 27
11
2021 - 09 - 20
13
2021 - 09 - 17
10
2021 - 09 - 16
9
2021 - 09 - 13
12
2021 - 06 - 29
7
2021 - 06 - 28
7
2021 - 06 - 25
10
2021 - 06 - 11
9
2021 - 06 - 07
8
2021 - 05 - 24
7
2021 - 05 - 21
15
2021 - 05 - 20
8
2021 - 05 - 11
7
2021 - 04 - 12
7
2021 - 03 - 24
8
2021 - 03 - 15
7
2020 - 12 - 09
7
Sector
Health technology
9
Manufacturing
1
Tags
Acquisition
3
Application
2
Approval
6
Authorized
2
Battery
3
Biopharma
2
Biotech-beach
2
Biotechnology
2
Brands
4
Cancer
4
Cardio
2
Cell carcinoma
3
Ceo
4
Children
3
China
2
Chip
3
Chmp
8
Communication
2
Conference
11
Contract
3
Covid
4
Device
2
Diabetes
11
Disease
4
Drug
5
Efruxifermin
4
Electronics
3
Ema
2
Energy
7
Europe
9
Ev
4
Events
6
Eye
2
Fibrosis
2
Financial results
9
Food
2
Glass
2
Growth
5
Immunotherapy
2
Leo
3
License
3
Liver
6
Market
15
Media
3
Merge
3
N/a
239
Nash
3
Offering
17
People
3
Positive
10
Publication
8
Regulatory
4
Research
5
Restaurant
4
Results
22
T-cell
3
Technology
4
Therapy
5
Treatment
13
Trial
14
Entities
Arrival
1
Biogen inc.
1
Biomarin pharmaceutical inc.
1
Bristol-myers squibb company
2
Fibrogen, inc
1
Incyte corporation
2
Madrigal pharmaceuticals, inc.
1
Morphosys ag
2
Xencor, inc.
2
Y-mabs therapeutics, inc.
1
Symbols
ARVL
1
BIIB
1
BMRN
1
BMY
2
FGEN
1
INCY
2
MDGL
1
MOR
2
XNCR
2
YMAB
1
Exchanges
Nasdaq
8
Nyse
2
Crawled Date
2021 - 06 - 25
10
Crawled Time
12:00
4
12:15
1
13:00
1
13:15
2
14:00
1
16:00
1
Source
investors.biomarin.com
1
www.biospace.com
4
www.globenewswire.com
4
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2021 - 06 - 25
tags :
Positive
save search
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
Published:
2021-06-25
(Crawled : 16:00)
- globenewswire.com
MDGL
M
|
$228.46
-1.94%
-1.98%
250K
|
Health Technology
|
125.74%
|
O:
0.63%
H:
1.02%
C:
-0.96%
presentation
ongoing
positive
phase 3
liver
trial
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Published:
2021-06-25
(Crawled : 14:00)
- globenewswire.com
FGEN
|
$1.265
-2.69%
-2.77%
1M
|
Health Technology
|
-95.63%
|
O:
2.75%
H:
0.79%
C:
-7.43%
disease
positive
anemia
chmp
kidney
Nationally Recognized Environmental Firm Expands Partnership: Attracts Prominent Former Troutman, Pepper Partner and Elevates Two Lawyers to Partnership Positions.
Published:
2021-06-25
(Crawled : 13:15)
- prnewswire.com
ARVL
|
News
|
$0.49
0.37%
2.5M
|
Manufacturing
|
-96.78%
|
O:
2.63%
H:
0.0%
C:
-5.18%
partnership
positive
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
Published:
2021-06-25
(Crawled : 13:15)
- globenewswire.com
YMAB
|
$15.09
-0.33%
-0.33%
450K
|
Health Technology
|
-56.14%
|
O:
0.35%
H:
2.4%
C:
-0.69%
treatment
positive
ema
designation
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published:
2021-06-25
(Crawled : 13:00)
- biospace.com/
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-47.04%
|
O:
0.06%
H:
2.35%
C:
0.75%
MOR
|
News
|
$18.03
0.45%
0.44%
400K
|
Health Technology
|
-6.87%
|
O:
2.89%
H:
0.23%
C:
-0.55%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-38.79%
|
O:
-0.71%
H:
1.74%
C:
1.53%
treatment
positive
chmp
t-cell
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published:
2021-06-25
(Crawled : 12:15)
- biospace.com/
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-47.04%
|
O:
0.06%
H:
2.35%
C:
0.75%
MOR
|
News
|
$18.03
0.45%
0.44%
400K
|
Health Technology
|
-6.87%
|
O:
2.89%
H:
0.23%
C:
-0.55%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-38.79%
|
O:
-0.71%
H:
1.74%
C:
1.53%
treatment
positive
chmp
t-cell
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published:
2021-06-25
(Crawled : 12:00)
- investors.biomarin.com
BMRN
|
News
S
|
$90.48
-0.43%
-0.43%
1.3M
|
Health Technology
|
8.73%
|
O:
0.66%
H:
1.39%
C:
0.55%
treatment
europe
drop
positive
children
growth
chmp
achondroplasia
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
Published:
2021-06-25
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-26.71%
|
O:
0.12%
H:
1.76%
C:
1.23%
positive
therapy
chmp
car-t
t-cell
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published:
2021-06-25
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-26.71%
|
O:
0.12%
H:
1.76%
C:
1.23%
disease
treatment
positive
therapy
cancer
iot
chmp
nivolumab
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
Published:
2021-06-25
(Crawled : 12:00)
- globenewswire.com
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
-44.11%
|
O:
-0.14%
H:
1.41%
C:
-0.21%
positive
chmp
biosimilar
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.